The Single Chain Deletion Mutant is an unglycosylated protein [355 amino acids] with a total molecular weight of 39 kDa. Reliance Life Sciences offers Single Chain Deletion Mutant. Reliance Life Sciences supplies Biopharmaceuticals, Plasma Proteins, Biosimilars, Pharmaceuticals, Oncology Products, Steroids, Hormones, Peptides, Formulations, Regenerative Medicine, etc. The Single Chain Deletion Mutant of model name MIRel [Reteplase] is characterized by reduced fibrin selectivity. In the absence of fibrin, reteplase and alteplase do not differ with respect to their activity as plasminogen activators, nor do they differ with respect to their inhibition by the plasminogen activator inhibitor type 1 [PAI-1]. The elimination of reteplase from the circulating plasma predominantly occurs in the liver. Because of the deletion of the fibronectin finger region, the epidermal growth factor domain and kringle 1, as well as the carbohydrate side chains, the hepatic elimination of the molecule is reduced. Consequently, plasma half life is increased to 14-18 minutes [versus 3-4 minutes with alteplase]. Each kit of MIRel or Single Chain Deletion Mutant contains two vials of 10 units of Reteplase, each sterile water for injection, two syringes and four needles
